Literature DB >> 24671638

Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis.

Thijs R van Oudheusden1, Hidde J Braam, Simon W Nienhuijs, Marinus J Wiezer, Bert van Ramshorst, Misha D Luyer, Valery E Lemmens, Ignace H de Hingh.   

Abstract

BACKGROUND: When peritoneal carcinomatosis (PC) is diagnosed during emergency surgery for colorectal cancer (CRC), further treatment with curative intent may seem futile given the known poor prognosis of both PC and emergency surgery. The aim of the current study was to investigate the feasibility and effectiveness of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for CRC patients who previously underwent emergency surgery in the presence of PC.
METHODS: All patients with synchronous PC of CRC referred to two tertiary centers between April 2005 and November 2013 were included in this study. Operative, postoperative and survival details were compared between patients presenting in an emergency or elective setting.
RESULTS: In total, 149 patients with synchronous PC underwent CRS and HIPEC. Amongst these patients, 36 (24.2 %) initially presented with acute symptoms requiring emergency surgery. Acute presentation did not result in a longer interval between the initial operation and HIPEC (2.2 vs. 2.1 months; P = 0.09). When comparing operative outcomes, no significant differences were found in blood loss (P = 0.47), operation time (P = 0.39), or completeness of cytoreduction (P = 0.97). In addition, complication rates, degree and types of complication did not differ between the groups. Median survival was 36.1 months for emergency presentation compared with 32.1 in the elective group (P = 0.73).
CONCLUSION: CRS + HIPEC may be performed safely in patients with PC of colorectal origin presenting with acute symptoms requiring emergency surgery. More importantly, the 5-year survival rate in these patients was equal to elective cases. This should be regarded as promising and therefore considered for these patients.

Entities:  

Mesh:

Year:  2014        PMID: 24671638     DOI: 10.1245/s10434-014-3655-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Alfonso García-Fadrique; Rafael Estevan Estevan; Luis Sabater Ortí
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 5.344

2.  Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery.

Authors:  Geert A Simkens; Vic J Verwaal; Valery E Lemmens; Harm J Rutten; Ignace H de Hingh
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 3.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence.

Authors:  Chao-Qun Huang; Yao Min; Shu-Yi Wang; Xiao-Jun Yang; Yang Liu; Bin Xiong; Yutaka Yonemura; Yan Li
Journal:  Oncotarget       Date:  2017-04-27

4.  Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  Aras Emre Canda; Cigdem Arslan; Cem Terzi; Selman Sokmen; Tugba Yavuzsen; Sevda Ozkardesler; Mehtat Unlu; Funda Obuz; Mehmet Fuzun
Journal:  World J Surg Oncol       Date:  2018-03-27       Impact factor: 2.754

5.  The impact of ultrasound-guided bilateral rectus sheath block in patients undergoing cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy - a retrospective study.

Authors:  Shaoheng Wang; Pengfei Liu; Teng Gao; Lei Guan; Tianzuo Li
Journal:  BMC Anesthesiol       Date:  2020-08-11       Impact factor: 2.217

6.  Cancer Survival Data Representation for Improved Parametric and Dynamic Lifetime Analysis.

Authors:  Lode K J Vandamme; Peter A A F Wouters; Gerrit D Slooter; Ignace H J T de Hingh
Journal:  Healthcare (Basel)       Date:  2019-10-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.